Clinical Trial

The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp

Study acronym: EPOASA
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of the study is to 1. To determine whether treatment with Erythropoiesis-stimulating agents (in the form of Aranesp®) affects platelet function, and how. 2. To determine whether salicylate treatment changes the effect of EPO (erythropoietin) on platelet function.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-03-30; most recent amendment 2024-01-24.
Status change: Not Yet Recruiting → Recruiting 2022-08-15
Trial Details
NCT Number NCT04330729
Lead Sponsor Zealand University Hospital
Conditions Erythropoietin Adverse Reaction
Enrollment 60 participants
Start Date 2020-04-15
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-01-25